Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNTO 6785/kg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg |
| 002 | EXPERIMENTAL | CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg |
| 003 | EXPERIMENTAL | CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg |
| 004 | PLACEBO_COMPARATOR | Placebo IV A single 30-minute IV infusion of placebo |
| 005 | EXPERIMENTAL | CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections |
| 006 | PLACEBO_COMPARATOR | Placebo SC A single SC dose of placebo administered in up to 3 SC injections |
| Name | Type | Description |
|---|---|---|
| Placebo IV | DRUG | A single 30-minute IV infusion of placebo |
| CNTO 6785 1 mg/kg IV | DRUG | A single 30-minute IV infusion of CNTO 6785 1 mg/kg |
| CNTO 6785 3 mg/kg IV | DRUG | A single 30-minute IV infusion of CNTO 6785 3 mg/kg |
| CNTO 6785 10 mg/kg IV | DRUG | A single 30-minute IV infusion of CNTO 6785 10 mg/kg |
| CNTO 6785 SC | DRUG | A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections |
| Placebo SC | DRUG | A single SC dose of placebo administered in up to 3 SC injections |
Inclusion Criteria: * Healthy adult volunteer with no clinically significant abnormalities as determined by the investigator (study physician) * Have a body mass index (BMI) between 19-30 kg/m2 * Be a non-smoker for at least 6 months prior to study participation * Women must be postmenopausal or su...
CNTO 6785 is an investigational small molecule being studied for the treatment of rheumatoid arthritis and moderate to severe chronic obstructive pulmonary disease (COPD). It has also been evaluated in healthy volunteers to assess safety, tolerability, pharmacokinetics, and immunogenicity.
CNTO 6785 is being developed by Johnson & Johnson (NYSE: JNJ). The company has sponsored clinical trials of the drug in healthy volunteers, rheumatoid arthritis, and chronic obstructive pulmonary disease.
CNTO 6785 has completed Phase 2 clinical trials for rheumatoid arthritis and chronic obstructive pulmonary disease. It also completed a Phase 1 study in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
CNTO 6785 has been studied in three completed trials. NCT01288196 was a Phase 1 study in healthy volunteers. NCT01909427 was a Phase 2 trial in rheumatoid arthritis patients on methotrexate. NCT01966549 was a Phase 2 trial in moderate to severe COPD patients.
CNTO 6785 is a distinct investigational compound developed by Johnson & Johnson. No alternative names for this drug have been disclosed in clinical trial records.